ArticleThe Journal of pediatrics2025
Growth Patterns in Shwachman-Diamond Syndrome: Findings from the North American Shwachman-Diamond Syndrome Registry.
Article in The Journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver disease in Shwachman-Diamond syndrome: A comprehensive characterization across the age spectrum.Journal of pediatric gastroenterology and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveTo characterize growth patterns in individuals with Shwachman-Diamond syndrome (SDS) in North America by generating SDS-specific growth curves and assessing the impact of hematopoietic stem cell transplant (HSCT) and growth hormone (GH) on growth. STUDY
designWe conducted a retrospective cohort study of 127 subjects with confirmed biallelic Shwachman-Bodian-Diamond syndrome mutations enrolled on the North American SDS Registry. Height-for-age, weight-for-age, and body mass index (BMI)-for-age Z-scores were analyzed and compared with Centers for Disease Control and Prevention and World Health Organization reference populations. The effects of HSCT and GH therapy on growth velocity and final height outcomes were assessed.
resultsIndividuals with SDS demonstrated significantly lower height-for-age Z-scores, with median adult height being approximately 7 cm shorter in females and 11 cm shorter in males compared with Centers for Disease Control and Prevention standards. Although weight-for-age was diminished, BMI-for-age trajectories were preserved. HSCT significantly reduced height-for-age Z-scores slope, and in a small subsample, GH therapy showed limited efficacy in improving final height.
conclusionsThis study of SDS across a diverse North American sample extends available growth data for this rare condition, confirming persistent short stature but normal BMI for age in SDS. HSCT was associated with a reduction in growth. No significant change in height velocity was observed with GH therapy. These data will inform clinical growth evaluation in SDS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.